Actinogen Medical Limited (ACW.AX)
AUD 0.03
(0.0%)
AUD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.61 Million AUD | -10.34% |
| 2023 | 1.8 Million AUD | 15.01% |
| 2022 | 1.56 Million AUD | 70.21% |
| 2021 | 920.32 Thousand AUD | -12.16% |
| 2020 | 1.04 Million AUD | 87.96% |
| 2019 | 557.39 Thousand AUD | -27.45% |
| 2018 | 768.25 Thousand AUD | -9.0% |
| 2017 | 844.25 Thousand AUD | 2.43% |
| 2016 | 824.2 Thousand AUD | 270.2% |
| 2015 | 222.64 Thousand AUD | 345.93% |
| 2014 | 49.92 Thousand AUD | -38.6% |
| 2013 | 81.31 Thousand AUD | -31.55% |
| 2012 | 118.8 Thousand AUD | 25.48% |
| 2011 | 94.68 Thousand AUD | -45.45% |
| 2010 | 173.57 Thousand AUD | 64.66% |
| 2009 | 105.41 Thousand AUD | 28.04% |
| 2008 | 82.33 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.18 Million AUD | 0.0% |
| 2024 Q4 | 1.61 Million AUD | 0.0% |
| 2024 FY | 1.61 Million AUD | -10.34% |
| 2023 Q4 | 1.8 Million AUD | 0.0% |
| 2023 FY | 1.8 Million AUD | 15.01% |
| 2023 Q2 | 1.74 Million AUD | 0.0% |
| 2022 Q2 | 1.08 Million AUD | 0.0% |
| 2022 FY | 1.56 Million AUD | 70.21% |
| 2022 Q4 | 1.56 Million AUD | 0.0% |
| 2021 Q2 | 1.1 Million AUD | 0.0% |
| 2021 FY | 920.32 Thousand AUD | -12.16% |
| 2021 Q4 | 920.32 Thousand AUD | 0.0% |
| 2020 Q2 | 1.13 Million AUD | 0.0% |
| 2020 FY | 1.04 Million AUD | 87.96% |
| 2020 Q4 | 1.04 Million AUD | 0.0% |
| 2019 FY | 557.39 Thousand AUD | -27.45% |
| 2019 Q2 | 2 Million AUD | 0.0% |
| 2019 Q4 | 557.39 Thousand AUD | 0.0% |
| 2018 Q4 | 768.25 Thousand AUD | 0.0% |
| 2018 FY | 768.25 Thousand AUD | -9.0% |
| 2018 Q2 | 1.04 Million AUD | 0.0% |
| 2017 Q2 | 603.69 Thousand AUD | 0.0% |
| 2017 Q4 | 844.25 Thousand AUD | 0.0% |
| 2017 FY | 844.25 Thousand AUD | 2.43% |
| 2016 FY | 824.2 Thousand AUD | 270.2% |
| 2016 Q4 | 824.2 Thousand AUD | 0.0% |
| 2016 Q2 | 190.73 Thousand AUD | 0.0% |
| 2015 Q4 | 222.64 Thousand AUD | 0.0% |
| 2015 Q2 | 96.52 Thousand AUD | 0.0% |
| 2015 FY | 222.64 Thousand AUD | 345.93% |
| 2014 Q2 | 48.03 Thousand AUD | 0.0% |
| 2014 Q4 | 49.92 Thousand AUD | 0.0% |
| 2014 FY | 49.92 Thousand AUD | -38.6% |
| 2013 Q4 | 81.31 Thousand AUD | 0.0% |
| 2013 Q2 | 112.43 Thousand AUD | 0.0% |
| 2013 Q1 | 112.43 Thousand AUD | -5.36% |
| 2013 FY | 81.31 Thousand AUD | -31.55% |
| 2013 Q3 | 81.31 Thousand AUD | -27.68% |
| 2012 FY | 118.8 Thousand AUD | 25.48% |
| 2012 Q4 | 118.8 Thousand AUD | 0.0% |
| 2011 FY | 94.68 Thousand AUD | -45.45% |
| 2011 Q4 | 94.68 Thousand AUD | 0.0% |
| 2010 Q4 | 173.57 Thousand AUD | 0.0% |
| 2010 FY | 173.57 Thousand AUD | 64.66% |
| 2009 FY | 105.41 Thousand AUD | 28.04% |
| 2009 Q4 | 105.41 Thousand AUD | 0.0% |
| 2008 Q4 | 82.33 Thousand AUD | 0.0% |
| 2008 FY | 82.33 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 54.401% |
| Acrux Limited | 5.68 Million AUD | 71.595% |
| AnteoTech Limited | 4.07 Million AUD | 60.362% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 33.434% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 21.456% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -426.437% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 70.227% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 52.861% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -71.567% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -338.427% |
| Biome Australia Limited | 5.37 Million AUD | 69.937% |
| Biotron Limited | 737.5 Thousand AUD | -119.031% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 56.717% |
| BTC Health Limited | 203.94 Thousand AUD | -692.049% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 87.383% |
| CSL Limited | 27.88 Billion AUD | 99.994% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 80.612% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 94.254% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -37.941% |
| Dimerix Limited | 13.89 Million AUD | 88.373% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 61.804% |
| Hexima Limited | 248.67 Thousand AUD | -549.603% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -54.488% |
| Immuron Limited | 2.84 Million AUD | 43.131% |
| Immutep Limited | 10.97 Million AUD | 85.288% |
| Imugene Limited | 33.14 Million AUD | 95.126% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -274.248% |
| Memphasys Limited | 5.59 Million AUD | 71.115% |
| Nanollose Limited | 465.64 Thousand AUD | -246.911% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 96.223% |
| Noxopharm Limited | 1.28 Million AUD | -25.357% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -1785.284% |
| Nyrada Inc. | 855.63 Thousand AUD | -88.792% |
| Orthocell Limited | 22.08 Million AUD | 92.685% |
| PharmAust Limited | 896.6 Thousand AUD | -80.165% |
| Patrys Limited | 691.36 Thousand AUD | -133.649% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 54.933% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 0.649% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 30.539% |
| PYC Therapeutics Limited | 10.18 Million AUD | 84.138% |
| Race Oncology Limited | 1.91 Million AUD | 15.709% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 96.385% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 89.836% |
| Starpharma Holdings Limited | 8.69 Million AUD | 81.428% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.352% |
| Tissue Repair Ltd | 1.35 Million AUD | -19.577% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 82.735% |